EQS-News
177
0 Kommentare
Rentschler Biopharma joins forces with Ikarovec to accelerate novel gene therapies for treatment of ophthalmic disease - Seite 3
BIO International Convention: Rentschler Biopharma will attend BIO in Boston, MA, June 5-8, 2023. Federico Pollano, Senior Vice President Business Development and Client Program Management Rentschler Biopharma, and Kassim Kolia, Vice President BD of Rentschler’s ATMP business, together with the BD team, will be available for additional information and requests at the Rentschler Biopharma booth (#1135). Meetings can also be scheduled through the partnering system. |
About Ikarovec
Established in 2018, Ikarovec is developing novel, differentiated gene therapies for major ophthalmic indications. Its lead product, a bicistronic gene therapy for geographic atrophy, is in preclinical studies, and earlier programmes are targeting wet-form age-related macular degeneration (AMD), diabetic macular oedema and intraocular hypertension. Building on intellectual property spun-out of Quethera (bought by Astellas in 2018), Ikarovec was founded by UKI2S and recently raised a £2.5m seed round with co-funding from LifeArc and Parkwalk Advisers. There is an experienced senior management team in place with business development and commercial success in ophthalmology and gene therapy – Dr. Peter Widdowson (ex Quethera) is Founder and Chief Technology Officer, and Piers Morgan (ex UniQure) is Executive Chairman.
About Rentschler Biopharma SE
Lesen Sie auch
Rentschler Biopharma is a leading contract development and manufacturing organization (CDMO) focused exclusively on client projects. The company offers process development and manufacturing of biopharmaceuticals, including adeno-associated virus (AAV) gene therapies, as well as related consulting activities, project management and regulatory support. Rentschler Biopharma's high quality is proven by its long-standing experience and excellence as a solution partner for its clients. A high-level quality management system, a well-established operational excellence philosophy and advanced technologies ensure product quality and productivity at each development and manufacturing step. Rentschler Biopharma is a family-owned company with about 1,200 employees, headquartered in Laupheim, Germany, with a second site in Milford, MA, USA. Rentschler ATMP Ltd., located in Stevenage, UK, is dedicated to cell and gene therapies.